Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Palisade Bio Inc (PALI)

Palisade Bio Inc (PALI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,244
  • Shares Outstanding, K 1,329
  • Annual Sales, $ 250 K
  • Annual Income, $ -12,300 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta 1.36
  • Price/Sales 12.92
  • Price/Cash Flow N/A
  • Price/Book 0.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -3.75
  • Growth Rate Est. (year over year) +26,740.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.18 +8.72%
on 10/31/24
3.90 -39.23%
on 10/22/24
-1.54 (-39.39%)
since 10/21/24
3-Month
2.18 +8.72%
on 10/31/24
4.32 -45.14%
on 10/21/24
-1.21 (-33.80%)
since 08/21/24
52-Week
2.18 +8.72%
on 10/31/24
22.35 -89.40%
on 01/29/24
-6.48 (-73.22%)
since 11/21/23

Most Recent Stories

More News
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

PALI : 2.43 (-0.41%)
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit

PALI : 2.43 (-0.41%)
Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

PALI : 2.43 (-0.41%)
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

PALI : 2.43 (-0.41%)
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

PALI : 2.43 (-0.41%)
Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting

PALI : 2.43 (-0.41%)
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

PALI : 2.43 (-0.41%)
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

PALI : 2.43 (-0.41%)
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023

- Live video webcast interactive Q&A with participating companies -

EVFM : 0.0111 (+11.00%)
GRI : 0.6695 (+4.77%)
MBRX : 2.69 (+0.93%)
XBIO : 3.90 (-2.26%)
AREC : 1.1000 (+3.77%)
CNSP : 0.1351 (+9.30%)
NVNO : 3.34 (-1.04%)
PALI : 2.43 (-0.41%)
Palisade Bio (NASDAQ: PALI) Awarded Fast Track Designation from U.S. FDA for LB1148

Palisade Bio, Inc. (NASDAQ: PALI) is engaged as a biopharmaceutical company, which is focused on the research and development of

PALI : 2.43 (-0.41%)

Business Summary

Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 3.31
2nd Resistance Point 3.10
1st Resistance Point 2.77
Last Price 2.43
1st Support Level 2.23
2nd Support Level 2.02
3rd Support Level 1.69

See More

52-Week High 22.35
Fibonacci 61.8% 14.65
Fibonacci 50% 12.27
Fibonacci 38.2% 9.88
Last Price 2.43
52-Week Low 2.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar